NYSE: EBSEmergent Biosolutions Inc Stock Ownership - Who owns Emergent Biosolutions?
Insider buying vs selling
Have Emergent Biosolutions Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Coleen Glessner | EVP Quality Ethics and CPL | 2026-06-08 | 2,018 | $8.00 | $16.14kSell |
| Paul Anthony Williams | SVP Products Business | 2026-06-08 | 694 | $8.00 | $5.55kSell |
| William Hartzel | SVP Bioservices | 2026-06-08 | 1,741 | $8.00 | $13.93kSell |
| Richard S. Lindahl | EVP Chief Financial Officer | 2026-06-08 | 3,964 | $8.00 | $31.71kSell |
| Donald W. Degolyer | Director | 2026-05-01 | 954 | $8.96 | $8.55kSell |
| Kathryn C. Zoon | Director | 2026-05-01 | 1,057 | $8.97 | $9.48kSell |
| Donald W. Degolyer | Director | 2026-05-01 | 14,527 | $8.36 | $121.45kSell |
| Kathryn C. Zoon | Director | 2026-05-01 | 16,145 | $8.36 | $134.97kSell |
| Sujata Tyagi Dayal | Director | 2026-05-01 | 12,781 | $8.36 | $106.85kSell |
| Sujata Tyagi Dayal | Director | 2026-05-01 | 980 | $8.94 | $8.76kSell |
EBS insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when EBS insiders and whales buy or sell their stock.
EBS Shareholders
What type of owners hold Emergent Biosolutions Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Fuad Elhibri | 49.87% | 25,733,310 | $219.51M | Insider |
| Intervac LLC | 8.42% | 4,344,250 | $37.06M | Insider |
| Blackrock Inc | 8.41% | 4,341,462 | $37.03M | Institution |
| State Street Corp | 5.52% | 2,849,701 | $24.31M | Institution |
| Dimensional Fund Advisors LP | 5.34% | 2,757,158 | $23.52M | Institution |
| American Century Companies Inc | 4.70% | 2,425,722 | $20.69M | Institution |
| Biopharm LLC | 4.39% | 2,265,043 | $19.32M | Insider |
| Vanguard Capital Management LLC | 4.38% | 2,257,995 | $19.26M | Institution |
| Robert Calvin Myers | 3.75% | 1,934,849 | $16.50M | Insider |
| Biovac LLC | 3.10% | 1,599,155 | $13.64M | Insider |
EBS vs Pharmaceutical Stocks
Emergent Biosolutions Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.